Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

08.05.25 12:00 Uhr

Werte in diesem Artikel
Aktien

56,00 EUR -0,50 EUR -0,88%

Financial release accessible online

BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release and certain supplemental tables that will be referenced during the call and include additional information supporting fiscal 2026 total Company and Hospital reported and organic revenue growth guidance.

Direct link to 4Q FY25 Earnings Release:
https://haemonetics.gcs-web.com/static-files/89295437-34ea-473c-ae6e-409a07328239

Direct link to Hospital Reported and Organic Revenue Growth Guidance Supplemental Tables:
https://haemonetics.gcs-web.com/static-files/320de990-2769-4b30-beca-eff1ca68bad1 

A replay of the conference call and webcast will be available for one year beginning on May 8, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                                     


Olga Guyette, Vice President-Investor Relations & Treasury         

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                           

(203) 733-4987

olga.guyette@haemonetics.com                                     

david.trenk@haemonetics.com                                                                               

 

Media Contact:         
Josh Gitelson, Sr. Director-Global Communications      
(781) 356-9776
josh.gitelson@haemonetics.com


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-4th-quarter-and-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302449085.html

SOURCE Haemonetics Corporation

In eigener Sache

Übrigens: Haemonetics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Haemonetics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Haemonetics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Haemonetics Corp.

Wer­bung

Analysen zu Haemonetics Corp.

DatumRatingAnalyst
07.08.2019Haemonetics OutperformBarrington Research
08.05.2019Haemonetics OutperformBarrington Research
09.08.2018Haemonetics OutperformBarrington Research
07.02.2018Haemonetics OutperformBarrington Research
08.11.2017Haemonetics OutperformBarrington Research
DatumRatingAnalyst
07.08.2019Haemonetics OutperformBarrington Research
08.05.2019Haemonetics OutperformBarrington Research
09.08.2018Haemonetics OutperformBarrington Research
07.02.2018Haemonetics OutperformBarrington Research
08.11.2017Haemonetics OutperformBarrington Research
DatumRatingAnalyst
07.02.2017Haemonetics Mkt PerformBarrington Research
07.11.2016Haemonetics HoldThe Benchmark Company
11.05.2016Haemonetics HoldThe Benchmark Company
05.11.2015Haemonetics HoldThe Benchmark Company
16.08.2006Update Haemonetics Corp.: HoldStanford Research
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Haemonetics Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen